<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:slash="http://purl.org/rss/1.0/modules/slash/">
  <channel>
    <title>Blog</title>
    <description>concrete5 Blog</description>
    <generator>Zend_Feed_Writer 2 (http://framework.zend.com)</generator>
    <link>https://acurastem.com/blog</link>
    <item>
      <title>AcuraStem Awarded Target ALS Grant to Advance Therapeutics Targeting a Core Driver of ALS</title>
      <description><![CDATA[PASADENA, Calif., March 10, 2026 — AcuraStem, a patient-based biotechnology company developing disease- modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ALS to advance therapeutics targeting SYF2, a recently identified regulator of TDP43 function. TDP-43 dysfunction is a central biological hallmark of ALS. ]]></description>
      <pubDate>Tue, 10 Mar 2026 06:52:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-awarded-target-als-grant-advance-therapeutics-targeting-core-driver-als</link>
      <guid>https://acurastem.com/blog/acurastem-awarded-target-als-grant-advance-therapeutics-targeting-core-driver-als</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Presents New iNeuroRX® Data at the 36th International Symposium on ALS/MND</title>
      <description><![CDATA[AcuraStem presented new poster data at the 36th International Symposium on ALS/MND, held December 5–7, 2025 in San Diego, USA, at the Loews Coronado Bay Resort. The Symposium, organized by the MND Association, is the largest annual conference dedicated to ALS and MND research and brings together researchers from around the world to share new findings.]]></description>
      <pubDate>Sun, 07 Dec 2025 07:39:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-presents-new-ineurorxr-data-36th-international-symposium-alsmnd</link>
      <guid>https://acurastem.com/blog/acurastem-presents-new-ineurorxr-data-36th-international-symposium-alsmnd</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Presents Advances in Patient-Derived Neurological Models and RNA Therapies at "Frontiers in Neuroscience"</title>
      <description><![CDATA[ At the symposium Frontiers in Neuroscience: Emerging Biology and Therapeutics, AcuraStem CEO Sam Alworth delivered a presentation titled “Using the iNeuroRx® Technology Platform to Develop Disease‑Modifying Treatments for ALS and FTD: Spotlight on UNC13A Candidate AS‑241.”]]></description>
      <pubDate>Fri, 25 Jul 2025 03:23:30 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-presents-advances-patient-derived-neurological-models-and-rna-therapies-frontiers-neuroscience</link>
      <guid>https://acurastem.com/blog/acurastem-presents-advances-patient-derived-neurological-models-and-rna-therapies-frontiers-neuroscience</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan Chang, Presents at the 15th Annual ALS Network Research Summit</title>
      <description><![CDATA[At the 15th annual ALS Network Research Summit, held on January 16, AcuraStem's Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan Chang delivered a key presentation titled 'Development of an UNC13A ASO for ALS.' ]]></description>
      <pubDate>Fri, 07 Feb 2025 15:33:58 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-associate-vice-president-discovery-and-early-development-dr-wen-hsuan-chang-presents-15th-annual-als-network-research</link>
      <guid>https://acurastem.com/blog/acurastem-associate-vice-president-discovery-and-early-development-dr-wen-hsuan-chang-presents-15th-annual-als-network-research</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem CSO Marcel van der Brug Presents at the 35th International Symposium on ALS/MND</title>
      <description><![CDATA[At the 35th International Symposium on ALS/MND, held from December 6-8, 2024, at the Montreal Convention Center, AcuraStem Chief Scientific Officer Marcel van der Brug delivered a key presentation titled 'Development of an UNC13A Cryptic Exon Skipping Antisense Oligonucleotide as a Treatment for ALS.]]></description>
      <pubDate>Fri, 20 Dec 2024 09:09:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-cso-marcel-van-der-brug-presents-35th-international-symposium-alsmnd</link>
      <guid>https://acurastem.com/blog/acurastem-cso-marcel-van-der-brug-presents-35th-international-symposium-alsmnd</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Welcomes Dr. Marcel van der Brug as Chief Scientific Officer</title>
      <description><![CDATA[AcuraStem announced the appointment of Marcel van der Brug, Ph.D., as Chief Scientific Officer. Dr. van der Brug is an accomplished neuroscientist with extensive expertise in neurodegenerative diseases and therapeutic development. ]]></description>
      <pubDate>Wed, 04 Dec 2024 16:47:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-welcomes-dr-marcel-van-der-brug-chief-scientific-officer</link>
      <guid>https://acurastem.com/blog/acurastem-welcomes-dr-marcel-van-der-brug-chief-scientific-officer</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem CEO Sam Alworth Champions RNA Therapeutics  at RNA Leaders USA Congress</title>
      <description><![CDATA[At the RNA Leaders USA Congress, held September 4-5, 2024, at the San Diego Convention Center, AcuraStem CEO Sam Alworth delivered a key presentation titled 'Accelerating the Development of More Effective Treatments for ALS & FTD Using the iNeuroRx® Technology Platform.']]></description>
      <pubDate>Mon, 09 Sep 2024 15:37:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-ceo-sam-alworth-champions-rna-therapeutics-rna-leaders-usa-congress</link>
      <guid>https://acurastem.com/blog/acurastem-ceo-sam-alworth-champions-rna-therapeutics-rna-leaders-usa-congress</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Secures $4 Million in Grant Funding from CIRM  to Advance UNC13A Program for ALS and FTD</title>
      <description><![CDATA[AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that it has successfully secured $4 million in grant funding from the California Institute for Regenerative Medicine (CIRM) as part of CIRM's Therapeutic Translational Research Projects program, which accelerates the preclinical development of innovative therapies.
]]></description>
      <pubDate>Tue, 03 Sep 2024 15:48:57 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-secures-4-million-grant-funding-cirm-advance-unc13a-program-als-and-ftd</link>
      <guid>https://acurastem.com/blog/acurastem-secures-4-million-grant-funding-cirm-advance-unc13a-program-als-and-ftd</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Appoints Dr. Rafael Renteria as  Principal Scientist, hiPSC Platform</title>
      <description><![CDATA[AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced the appointment of Dr. Rafael Renteria as Principal Scientist, hiPSC Platform.]]></description>
      <pubDate>Mon, 26 Aug 2024 15:46:08 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-appoints-dr-rafael-renteria-principal-scientist-hipsc-platform</link>
      <guid>https://acurastem.com/blog/acurastem-appoints-dr-rafael-renteria-principal-scientist-hipsc-platform</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem CEO Sam Alworth to Speak at RNA Leaders USA Congress</title>
      <description><![CDATA[AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that CEO Sam Alworth has been invited to speak at the RNA Leaders USA Congress, scheduled for September 4-5, 2024, at the San Diego Convention Center.]]></description>
      <pubDate>Mon, 12 Aug 2024 17:35:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-ceo-sam-alworth-speak-rna-leaders-usa-congress</link>
      <guid>https://acurastem.com/blog/acurastem-ceo-sam-alworth-speak-rna-leaders-usa-congress</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Welcomes Dr. Ananya Sengupta as  Associate Director of Program Management</title>
      <description><![CDATA[AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced the appointment of Dr. Ananya Sengupta as Associate Director of Program Management]]></description>
      <pubDate>Mon, 24 Jun 2024 11:01:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-welcomes-dr-ananya-sengupta-associate-director-program-management</link>
      <guid>https://acurastem.com/blog/acurastem-welcomes-dr-ananya-sengupta-associate-director-program-management</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Dr. Wen-Hsuan Chang to Speak at 5th International Oligonucleotides and Peptides Conference</title>
      <description><![CDATA[AcuraStem’s Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan (Wen) Chang, will present at the 5th International Oligonucleotides and Peptides Conference (IOPC) on June 26, 2024, in Milan]]></description>
      <pubDate>Fri, 21 Jun 2024 15:35:00 +0000</pubDate>
      <link>https://acurastem.com/blog/dr-wen-hsuan-chang-speak-5th-international-oligonucleotides-and-peptides-conference</link>
      <guid>https://acurastem.com/blog/dr-wen-hsuan-chang-speak-5th-international-oligonucleotides-and-peptides-conference</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Names Dr. Wen-Hsuan Chang  Associate Vice President, Discovery and Early Development</title>
      <description><![CDATA[AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced it has named Dr. Wen-Hsuan Chang as Associate Vice President of Discovery and Early Development]]></description>
      <pubDate>Tue, 18 Jun 2024 18:41:18 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-names-dr-wen-hsuan-chang-associate-vice-president-discovery-and-early-development</link>
      <guid>https://acurastem.com/blog/acurastem-names-dr-wen-hsuan-chang-associate-vice-president-discovery-and-early-development</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Sponsors IgNight ALS, Celebrating Steve Gleason's Legacy and Inspiring Hope in the ALS Community</title>
      <description><![CDATA[AcuraStem proudly sponsored the recent IgNight ALS event in Washington, D.C., a poignant evening dedicated to celebrating Steve Gleason and his profound contributions to the ALS community]]></description>
      <pubDate>Tue, 18 Jun 2024 18:32:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-sponsors-ignight-als-celebrating-steve-gleasons-legacy-and-inspiring-hope-als-community</link>
      <guid>https://acurastem.com/blog/acurastem-sponsors-ignight-als-celebrating-steve-gleasons-legacy-and-inspiring-hope-als-community</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Welcomes New Team Member and Promotes Key Leaders to Propel Neurodegenerative Disease Research</title>
      <description><![CDATA[AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced the expansion of its team with three new team members, bringing a fresh influx of expertise to its pioneering platform.]]></description>
      <pubDate>Mon, 03 Jun 2024 16:19:55 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-welcomes-new-team-member-and-promotes-key-leaders-propel-neurodegenerative-disease-research</link>
      <guid>https://acurastem.com/blog/acurastem-welcomes-new-team-member-and-promotes-key-leaders-propel-neurodegenerative-disease-research</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Dr. Wen-Hsuan Chang to Present at 3rd Annual ALS Drug Development Summit</title>
      <description><![CDATA[AcuraStem’s Associate Vice President, Dr. Wen-Hsuan (Wen) Chang, to Present at 3rd Annual ALS Drug Development Summit and Participate in Panel and Roundtable Discussions]]></description>
      <pubDate>Fri, 17 May 2024 18:24:00 +0000</pubDate>
      <link>https://acurastem.com/blog/dr-wen-hsuan-chang-present-3rd-annual-als-drug-development-summit</link>
      <guid>https://acurastem.com/blog/dr-wen-hsuan-chang-present-3rd-annual-als-drug-development-summit</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem CEO Sam Alworth to Highlight Groundbreaking  UNC13A Therapy Development at MDA Clinical &amp; Scientific Conference 2024</title>
      <description><![CDATA[AcuraStem CEO, Sam Alworth, will present on the company's trailblazing approach to  amyotrophic lateral sclerosis (ALS) therapies at the MDA Clinical & Scientific Conference on March 4th.]]></description>
      <pubDate>Tue, 27 Feb 2024 20:12:19 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-ceo-sam-alworth-highlight-groundbreaking-unc13a-therapy-development-mda-clinical-scientific-conference-2024</link>
      <guid>https://acurastem.com/blog/acurastem-ceo-sam-alworth-highlight-groundbreaking-unc13a-therapy-development-mda-clinical-scientific-conference-2024</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>Dr. Wen-Hsuan Chang Highlights UNC13A Program at 14th Annual California ALS Research Summit</title>
      <description><![CDATA[AcuraStem’s Head of Target Validation, Dr. Wen-Hsuan Chang,  presented an update on the company's innovative UNC13A program at the 14th Annual California ALS Research Summit on January 19, 2024]]></description>
      <pubDate>Tue, 27 Feb 2024 17:39:00 +0000</pubDate>
      <link>https://acurastem.com/blog/dr-wen-hsuan-chang-highlights-unc13a-program-14th-annual-california-als-research-summit</link>
      <guid>https://acurastem.com/blog/dr-wen-hsuan-chang-highlights-unc13a-program-14th-annual-california-als-research-summit</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Secures $7 Million in Funding Support from  NIH and DOD to Accelerate Therapies for ALS and FTD</title>
      <description><![CDATA[AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trial]]></description>
      <pubDate>Tue, 30 Jan 2024 01:00:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-secures-7-million-funding-support-nih-and-dod-accelerate-therapies-als-and-ftd</link>
      <guid>https://acurastem.com/blog/acurastem-secures-7-million-funding-support-nih-and-dod-accelerate-therapies-als-and-ftd</guid>
      <slash:comments>0</slash:comments>
    </item>
    <item>
      <title>AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics</title>
      <description><![CDATA[ Agreement enables the development of therapeutics, including AcuraStem’s AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase]]></description>
      <pubDate>Mon, 25 Sep 2023 09:30:00 +0000</pubDate>
      <link>https://acurastem.com/blog/acurastem-enters-license-agreement-takeda-advance-pikfyve-therapeutics</link>
      <guid>https://acurastem.com/blog/acurastem-enters-license-agreement-takeda-advance-pikfyve-therapeutics</guid>
      <slash:comments>0</slash:comments>
    </item>
  </channel>
</rss>
